{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:16:50Z","timestamp":1791685010233,"version":"4.3.4"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    <jats:italic>Toxoplasma gondii<\/jats:italic>\n                    , a specialized intracellular parasite, causes a widespread zoonotic disease and is a severe threat to social and economic development. There is a lack of effective drugs and vaccines against\n                    <jats:italic>T. gondii<\/jats:italic>\n                    infection. Recently, mRNA vaccines have been rapidly developed, and their packaging materials and technologies are well established. In this study, TGGT1_216200 (TG_200), a novel molecule from\n                    <jats:italic>T. gondii<\/jats:italic>\n                    , was identified using bioinformatic screening analysis. TG_200 was purified and encapsulated with a lipid nanoparticle (LNP) to produce the TG_200 mRNA-LNP vaccine. The immune protection provided by the new vaccine and its mechanisms after immunizing BABL\/C mice\n                    <jats:italic>via<\/jats:italic>\n                    intramuscular injection were investigated. There was a strong immune response when mice were vaccinated with TG_200 mRNA-LNP. Elevated levels of anti-\n                    <jats:italic>T. gondii<\/jats:italic>\n                    -specific immunoglobulin G (IgG), and a higher IgG2a-to-IgG1 ratio was observed. The levels of interleukin-12 (IL-12), interferon-\u03b3 (IFN-\u03b3), IL-4, and IL-10 were also elevated. The result showed that the vaccine induced a mixture of Th1 and Th2 cells, and Th1-dominated humoral immune response. Significantly increased antigen-specific splenocyte proliferation was induced by TG_200 mRNA-LNP immunization. The vaccine could also induce\n                    <jats:italic>T. gondii<\/jats:italic>\n                    -specific cytotoxic T lymphocytes (CTLs). The expression levels of interferon regulatory factor 8 (IRF8), T-Box 21 (T-bet), and nuclear factor kappa B (NF-\u03baB) were significantly elevated after TG_200 mRNA-LNP immunization. The levels of CD83, CD86, MHC-I, MHC-II, CD8, and CD4 molecules were also higher. The results indicated that TG_200 mRNA-LNP produced specific cellular and humoral immune responses. Most importantly, TG_200 mRNA-LNP immunized mice survived significantly longer (19.27 \u00b1 3.438 days) than the control mice, which died within eight days after\n                    <jats:italic>T. gondii<\/jats:italic>\n                    challenge (\n                    <jats:italic>P&amp;lt;<\/jats:italic>\n                    0.001). The protective effect of adoptive transfer was also assessed, and mice receiving serum and splenocytes from mice immunized with TG_200 mRNA-LNP showed improved survival rates of 9.70 \u00b1 1.64 days and, 13.40 \u00b1 2.32 days, respectively (\n                    <jats:italic>P&amp;lt;<\/jats:italic>\n                    0.001). The results suggested that TG_200 mRNA-LNP is a safe and promising vaccine against\n                    <jats:italic>T. gondii<\/jats:italic>\n                    infection.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2023.1161507","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T01:30:42Z","timestamp":1681435842000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Immunization with a novel mRNA vaccine, TGGT1_216200 mRNA-LNP, prolongs survival time in BALB\/c mice against acute toxoplasmosis"],"prefix":"10.3389","volume":"14","author":[{"given":"Yizhuo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05013-11","article-title":"Epidemiology of and diagnostic strategies for toxoplasmosis","volume":"25","author":"Robert-Gangneux","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16412-X","article-title":"Toxoplasmosis","volume":"363","author":"Montoya","year":"2004","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sby082","article-title":"Toxoplasma gondii: biological parameters of the connection to schizophrenia","volume":"44","author":"Xiao","year":"2018","journal-title":"Schizophr bulletin."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00242","article-title":"Advances and challenges in understanding cerebral toxoplasmosis","volume":"10","author":"Schl\u00fcter","year":"2019","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100882","DOI":"10.1016\/j.preteyeres.2020.100882","article-title":"Pathogenesis of ocular toxoplasmosis","volume":"81","author":"Smith","year":"2021","journal-title":"Prog retinal eye Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2020.08.005","article-title":"Toxoplasma gondii: AnUnderestimated Threat","volume":"36","author":"Milne","year":"2020","journal-title":"Trends Parasitol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1655258","article-title":"Perspective on current and emerging drugs in the treatment of acute and chronic toxoplasmosis","volume":"131","author":"Lapinskas","year":"2019","journal-title":"Postgraduate Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00057-17","article-title":"Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice","volume":"31","author":"Dunay","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9121413","article-title":"Human papillomavirus vaccine efficacy and effectiveness against cancer","volume":"9","author":"Kamolratanakul","year":"2021","journal-title":"Vaccines (Basel)."},{"key":"B10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 vaccine: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1017\/S003118200000144X","article-title":"A commercial vaccine for ovine toxoplasmosis","author":"Buxton","year":"1995","journal-title":"Parasitology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2019.01.005","article-title":"Advances in the development of anti-toxoplasma gondii vaccines: challenges, opportunities, and perspectives","volume":"35","author":"Wang","year":"2019","journal-title":"Trends Parasitol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050413","article-title":"Advances in toxoplasma gondii vaccines: current strategies and challenges for vaccine development","volume":"9","author":"Chu","year":"2021","journal-title":"Vaccines (Basel)."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2432","article-title":"DNA Vaccines: ready for prime time","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat Rev Genet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent advances in mRNA vaccine technology","volume":"65","author":"Pardi","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.actbio.2021.06.023","article-title":"From influenza to COVID-19: lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases","volume":"131","author":"Pilkington","year":"2021","journal-title":"Acta biomaterialia."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00418","article-title":"GRA24-based DNA vaccine prolongs survival in mice challenged with a virulent toxoplasma gondii strain","volume":"10","author":"Zheng","year":"2019","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-022-02998-9","article-title":"Toxoplasma gondii vaccine candidates: a concise review","volume":"192","author":"Mamaghani","year":"2023","journal-title":"Irish J Med sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70067-2","article-title":"Serodiagnosis of schistosoma japonicum infection: genome-wide identification of a protein marker, and assessment of its diagnostic validity in a field study in China","volume":"14","author":"Xu","year":"2014","journal-title":"Lancet Infect diseases."},{"key":"B20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1051\/parasite\/2016017","article-title":"Epitope analysis and protection by a ROP19 DNA vaccine against toxoplasma gondii","volume":"23","author":"Zhou","year":"2016","journal-title":"Parasite"},{"key":"B21","doi-asserted-by":"publisher","first-page":"028","DOI":"10.14411\/fp.2016.028","article-title":"Analysis of structures and epitopes of a novel secreted protein MYR1 in toxoplasma gondii","volume":"63","author":"Zhou","year":"2016","journal-title":"Folia parasitol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"101414","DOI":"10.1016\/j.cimid.2020.101414","article-title":"Toxoplasma gondii surface antigen 1 (SAG1) as a potential candidate to develop vaccine against toxoplasmosis: a systematic review","volume":"69","author":"Pagheh","year":"2020","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/v14020401","article-title":"mRNA vaccine development for emerging animal and zoonotic diseases","volume":"14","author":"Le","year":"2022","journal-title":"Viruses"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.714170","article-title":"Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis","volume":"12","author":"Sharif","year":"2021","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41541-021-00345-0","article-title":"Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice","volume":"6","author":"Mallory","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.00605","article-title":"Induction of protective immunity against toxoplasma gondii in mice by nucleoside triphosphate hydrolase-II (NTPase-II) self-amplifying RNA vaccine encapsulated in lipid nanoparticle (LNP)","volume":"8","author":"Luo","year":"2017","journal-title":"Front Microbiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41541-022-00563-0","article-title":"Toxoplasmosis vaccines: what we have and where to go","volume":"7","author":"Zhang","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.686004","article-title":"Protective immunity induced by TgMIC5 and TgMIC16 DNA vaccines against toxoplasmosis","volume":"11","author":"Zhu","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2015.1061938","article-title":"Protective efficacy of two novel DNA vaccines expressing toxoplasma gondii rhomboid 4 and rhomboid 5 proteins against acute and chronic toxoplasmosis in mice","volume":"14","author":"Zhang","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"B31","doi-asserted-by":"publisher","first-page":"104435","DOI":"10.1016\/j.micpath.2020.104435","article-title":"Enhancing immune responses by a novel multi-epitope ROP8 DNA vaccine plus interleukin-12 plasmid as a genetic adjuvant against acute toxoplasma gondii infection in BALB\/c mice","volume":"147","author":"Foroutan","year":"2020","journal-title":"Microb Pathog"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2018.00163","article-title":"Chitosan microsphere used as an effective system to deliver a linked antigenic peptides vaccine protect mice against acute and chronic toxoplasmosis","volume":"8","author":"Guo","year":"2018","journal-title":"Front Cell Infect Microbiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwv040","article-title":"Investigation of the protective properties of glycosylphosphatidylinositol-based vaccine candidates in a toxoplasma gondii mouse challenge model","volume":"25","author":"G\u00f6tze","year":"2015","journal-title":"Glycobiology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.7774\/cevr.2021.10.1.59","article-title":"Immunoinformatic analysis of immunogenic b- and T-cell epitopes of MIC4 protein to designing a vaccine candidate against toxoplasma gondii through an in-silico approach","volume":"10","author":"Ghaffari","year":"2021","journal-title":"Clin Exp Vaccine Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1756-3305-6-125","article-title":"Screening and identification of novel b cell epitopes of toxoplasma gondii SAG1","volume":"6","author":"Wang","year":"2013","journal-title":"Parasit Vectors."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2015.1098539","article-title":"Recent advances in developing vaccines against toxoplasma gondii: an update","volume":"14","author":"Zhang","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e1530","DOI":"10.1002\/wnan.1530","article-title":"Nanoscale platforms for messenger RNA delivery","volume":"11","author":"Li","year":"2019","journal-title":"Wiley Interdiscip Rev Nanomed nanobiotechnol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2017.5","article-title":"Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems","volume":"24","author":"Guan","year":"2017","journal-title":"Gene Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","article-title":"Self-assembled mRNA vaccines","volume":"170","author":"Kim","year":"2021","journal-title":"Advanced Drug delivery Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-019-0591-y","article-title":"The onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat nanotechnol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMc2036242","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"384","author":"Vergnes","year":"2021","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.01733","article-title":"SAG4 DNA and peptide vaccination provides partial protection against t. gondii infection in BALB\/c mice","volume":"8","author":"Zhou","year":"2017","journal-title":"Front Microbiol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2011.03.009","article-title":"Innate responses to toxoplasma gondii in mice and humans","volume":"27","author":"Pifer","year":"2011","journal-title":"Trends Parasitol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.02965","article-title":"Protective efficacy against acute and chronic toxoplasma gondii infection induced by immunization with the DNA vaccine TgDOC2C","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Microbiol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.787635","article-title":"Enhancing immune responses to a DNA vaccine encoding toxoplasma gondii GRA7 using calcium phosphate nanoparticles as an adjuvant","volume":"11","author":"Sun","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00281-012-0339-3","article-title":"Immune response and immunopathology during toxoplasmosis","volume":"34","author":"Dupont","year":"2012","journal-title":"Semin immunopathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01615-14","article-title":"Type II toxoplasma gondii induction of CD40 on infected macrophages enhances interleukin-12 responses","volume":"82","author":"Morgado","year":"2014","journal-title":"Infect Immun"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpara.2014.03.004","article-title":"Natural killer cell intrinsic toll-like receptor MyD88 signaling contributes to IL-12-dependent IFN-\u03b3 production by mice during infection with toxoplasma gondii","volume":"44","author":"Ge","year":"2014","journal-title":"Int J parasitol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nri3210","article-title":"Interferon-inducible effector mechanisms in cell-autonomous immunity","volume":"12","author":"MacMicking","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399411002018","article-title":"Interferon-gamma- and perforin-mediated immune responses for resistance against toxoplasma gondii in the brain","volume":"13","author":"Suzuki","year":"2011","journal-title":"Expert Rev Mol Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"798","DOI":"10.4049\/jimmunol.157.2.798","article-title":"In the absence of endogenous IL-10, mice acutely infected with toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha","volume":"157","author":"Gazzinelli","year":"1996","journal-title":"J Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00734","article-title":"The virulence-related MYR1 protein of toxoplasma gondii as a novel DNA vaccine against toxoplasmosis in mice","volume":"10","author":"Zheng","year":"2019","journal-title":"Front Microbiol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00721","article-title":"The CD83 molecule - an important immune checkpoint","volume":"11","author":"Grosche","year":"2020","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1379\/CSC-138R.1","article-title":"Toxoplasma gondii-derived heat shock protein 70 stimulates maturation of murine bone marrow-derived dendritic cells via toll-like receptor 4","volume":"11","author":"Aosai","year":"2006","journal-title":"Cell Stress chaperones."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.4.2589-2595.2001","article-title":"Immunological studies of chronic ocular toxoplasmosis: up-regulation of major histocompatibility complex class I and transforming growth factor beta and a protective role for interleukin-6","volume":"69","author":"Lyons","year":"2001","journal-title":"Infect Immun"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00097-13","article-title":"CD4+ T cells: guardians of the phagosome","volume":"27","author":"Tubo","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.04.002","article-title":"Mechanisms and dynamics of T cell-mediated cytotoxicity in vivo","volume":"38","author":"Halle","year":"2017","journal-title":"Trends Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.839489","article-title":"Nano vaccines for t. gondii ribosomal P2 protein with nanomaterials as a promising DNA vaccine against toxoplasmosis","volume":"13","author":"Yu","year":"2022","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00683","article-title":"Activation of NF-kappaB by toxoplasma gondii correlates with increased expression of antiapoptotic genes and localization of phosphorylated IkappaB to the parasitophorous vacuole membrane","volume":"116","author":"Molestina","year":"2003","journal-title":"J Cell Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cr.7310018","article-title":"IRF family proteins and type I interferon induction in dendritic cells","volume":"16","author":"Tailor","year":"2006","journal-title":"Cell Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.09.007","article-title":"The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses","volume":"37","author":"Zhu","year":"2012","journal-title":"Immunity"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008299","article-title":"T-Bet-dependent ILC1- and NK cell-derived IFN-\u03b3 mediates cDC1-dependent host resistance against toxoplasma gondii","volume":"17","author":"L\u00f3pez-Yglesias","year":"2021","journal-title":"PloS Pathog"},{"key":"B66","doi-asserted-by":"publisher","first-page":"103601","DOI":"10.1016\/j.micpath.2019.103601","article-title":"Protective efficacy induced by DNA prime and recombinant protein boost vaccination with toxoplasma gondii GRA14 in mice","volume":"134","author":"Pagheh","year":"2019","journal-title":"Microb Pathog"},{"key":"B67","doi-asserted-by":"publisher","first-page":"103560","DOI":"10.1016\/j.micpath.2019.103560","article-title":"Evaluation of protective immunity induced by recombinant calcium-dependent protein kinase 1 (TgCDPK1) protein against acute toxoplasmosis in mice","volume":"133","author":"Huang","year":"2019","journal-title":"Microb Pathog"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00909","article-title":"Immune protection of rhoptry protein 21 (ROP21) of toxoplasma gondii as a DNA vaccine against toxoplasmosis","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Microbiol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.parint.2014.01.002","article-title":"CTL induction by DNA vaccine with toxoplasma gondii-HSP70 gene","volume":"63","author":"Chu","year":"2014","journal-title":"Parasitol Int"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900410","article-title":"Toxoplasma gondii tkl1 deletion mutant is a promising vaccine against acute, chronic, and congenital toxoplasmosis in mice","volume":"204","author":"Wang","year":"2020","journal-title":"J Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.85955","article-title":"Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against toxoplasma gondii","volume":"1","author":"El Bissati","year":"2016","journal-title":"JCI Insight"},{"key":"B72","doi-asserted-by":"publisher","first-page":"104764","DOI":"10.1016\/j.micpath.2021.104764","article-title":"Protective efficacy by a novel multi-epitope vaccine, including MIC3, ROP8, and SAG1, against acute toxoplasma gondii infection in BALB\/c mice","volume":"153","author":"Dodangeh","year":"2021","journal-title":"Microb Pathog"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1161507\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T01:30:48Z","timestamp":1681435848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1161507\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":72,"alternative-id":["10.3389\/fimmu.2023.1161507"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1161507","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"article-number":"1161507"}}